Daria M. Medvedeva

Daria M. Medvedeva

Auto-generated profile, based on publicly available information

Daria M. Medvedeva

Saint Petersburg State Chemical and Pharmaceutical University (SPCPU)

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2021 in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
Verified
Journal Article
Open access
PDF file
DMD. M. Medvedeva
D. M. Medvedeva
INI. A. Narkevich
I. A. Narkevich
ONOksana Nemyatykh
Oksana Nemyatykh
Objective: to analyze the availability and affordability of pharmaceuticals for children in need of palliative care.Materials and methods. The price, affordability and physical availability of pharmaceuticals for children in need of palliative care were analyzed in accordance with the Health Action International guidelines of the World Health Organization. Linear distribution index (LDI) was calculated to produce the best estimates of availability. Research data was sourced from AlphaRM (as of April 26, 2021) and International Medicine Reference Piece Data. The data array was based on the fiscal data provided by pharmacies. The research was carried out on the total population of pharmacies in the Russian Federation (69,050 pharmacies) and in St. Petersburg (1986 pharmacies).Results. Pharmaceutical price and affordability estimates show that low-priced generics, which cover over 75% of the whole range, have the most optimal median value of the median price ratio (MPR<1) on top of low affordability ratios (AR1). Midazolam (AR=2.494), morphine (AR=2.324), and celecoxib (AR=1.373) had low affordability. Notably, prescription-based pharmaceuticals such as diazepam, midazolam, tramadol, morphine, and fentanyl had the lowest physical availability scores (LDI60%).Conclusions. The results call for better organizational action in the pharmaceutical industry to provide due drug regimens to children in need of palliative care.

8 December 2023 in Medical Technologies. Assessment and Choice
Verified
Journal Article
Closed access
INI.A. Narkevich
I.A. Narkevich
DMD.M. Medvedeva
D.M. Medvedeva
ONOksana Nemyatykh
Oksana Nemyatykh
PKP.V. Kuznetsova
P.V. Kuznetsova
ITI.O. Trushnikova
I.O. Trushnikova
Objective. To analyze state procurements of compounded medecines in the Russian Federation. Material and methods. We analyzed data from a unified information system designed for state procurement. Excel database containing information on prescription, dosage form, quantity, cost, year of purchase, region, customer and contractor was created. The study covered 1.255 contracts between January 1, 2016 and December 1, 2022. Results. Consumption of pharmacy-made medicines procured by public medical organisations decreased by 49% in monetary value and 46% in units throughout the study period (2016—2022). Medicines produced upon the request of medical organizations constituted 0.001% of total volume in Russian pharmaceutical market. The procurement structure primarily consists of low-cost dosage forms such as solutions for external use (74%) and powders (5%). Compounding pharmacies are still essential for pediatric medical care, but their potential for enhancing medicine accessibility in other therapeutic fields remains largely untapped. Conclusion. Pharmaceutical compounding in Russia presently relies on conventional methodologies and primarily encompasses low-profit product offerings with conventional one- and two-component formulations. Preservation and development of small-scale and personalised pharmaceutical compounding necessitate regulatory adjustments, reassessment of product selection policies, creation of medications aligned with contemporary pharmaceutical technology standards, modernization of pharmacy production facilities and higher qualification of pharmaceutical staff.

1 January 2022 in Medical Technologies. Assessment and Choice
Verified
Journal Article
Closed access
INI.A. Narkevich
I.A. Narkevich
ONOksana Nemyatykh
Oksana Nemyatykh
DMD.M. Medvedeva
D.M. Medvedeva
KAK.M. Akpaeva
K.M. Akpaeva
ZSZuriyadda Sakipova
Zuriyadda Sakipova
ZMZh.V. Mironenkova
Zh.V. Mironenkova
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить параметры потребления антиретровирусных лекарственных препаратов (АРВП) в рамках фармацевтического рынка Республики Казахстан. МАТЕРИАЛ И МЕТОДЫ Информационную базу исследования составили данные аналитического агентства IQVIA за период с 2014 по 2020 г. Использованы методы сравнительного анализа, динамических рядов, а также методология ATC/DDD (Anatomical Therapeutic Chemical/Defined Daily Dose). РЕЗУЛЬТАТЫ Сравнительный анализ казахской и международной практик антиретровирусной терапии позволяет утверждать, что ряд АРВП, используемых за рубежом, в том числе позиции нуклеозидных ингибиторов обратной транскриптазы (НИОТ), ингибиторов протеазы (ИП), ингибиторов интегразы (ИИ), а также антагонистов рецепторов CCR5 отсутствуют в ассортиментной матрице, определяющей возможности фармакотерапии ВИЧ-инфицированных пациентов в Республике Казахстан. Оценка динамики потребления АРВП свидетельствует о повышении уровня доступности терапии, что выражается в увеличении объема реализованного спроса в натуральном выражении на 84% в условиях снижения уровня продаж в стоимостных показателях на 17%. Структуризация потребления АРВП по странам-производителям показала, что максимальный вклад в структуру реализации вносят зарубежные фармацевтические компании: в стоимостном выражении — США (52%), в натуральных единицах — Индии (62%). Сравнительная оценка объема потребления каждой фармакотерапевтической группы демонстрирует преобладание комбинированных АРВП, содержащих 2 НИОТ и 1 ненуклеозидный ингибитор обратной транскриптазы (ННИОТ) и комбинированных АРВП, содержащих 2 НИОТ — в натуральном выражении, ИИ и ИП — в стоимостном выражении. Показано, что в Республике Казахстан соблюдаются рекомендации ВОЗ по минимизации интенсивности формирования и распространения лекарственной устойчивости ВИЧ к антиретровирусной терапии. ЗАКЛЮЧЕНИЕ Полученные результаты необходимы для обоснования перспектив дальнейших исследований в области совершенствования лекарственного обеспечения пациентов с ВИЧ-инфекцией, направленных на расширение национального портфеля лекарственных препаратов в рамках сегмента антиретровирусных лекарственных средств.

12 December 2019 in Pharmacy Formulas
Verified
Journal Article
Open access
PDF file
INIgor A. Narkevich
Igor A. Narkevich
ONOksana Nemyatykh
Oksana Nemyatykh
DMDaria M. Medvedeva
Daria M. Medvedeva
Improvement of the palliative care system is one of the development priorities of health care system in Russia, as well as all around the world. This work represents the review of scientific literature dedicated to evaluation of the pharmaceutical staff as a member of interdisciplinary team providing palliative care for children. The major improvement priorities of drug provision of children in need of palliative care, including the area of drugs range, inventory management, compounding pharmacies activity, pharmaceutical information and counseling, were set up on the basis of the comparative analysis of Russian and international pharmaceutical practices.

9 October 2026 in Drug development & registration
Verified
Journal Article
Open access
PDF file
Veronika ShikovaVeronika Shikova
Veronika Shikova
DMD. M. Medvedeva
D. M. Medvedeva
INI. A. Narkevich
I. A. Narkevich
ONOksana Nemyatykh
Oksana Nemyatykh
EFE. V. Flisyuk
E. V. Flisyuk
АША. Н. Шиков
А. Н. Шиков
Introduction. Phytomedicines (PM) are medicinal products that contain at least one plant-based component with established pharmacological activity. The global PM market has demonstrated steady growth for many years. Despite growing demand, the Russian PM market remains understudied. Aim. To assess the current state and structure of the Russian PM market over the period 2020–2025. Materials and methods. The data from the analytical agency DSM Group (2020–2025) were used for the market assessment. PM containing at least one herbal-based component were included in our analysis. A modified Boston Consulting Group (BCG) matrix was used for the strategic assessment of the PM market segments. Results and discussion. In 2025, the total Russian PM reached 152.6 bln rubles ($1.9 bln) and 393.4 mln packs. PM account for 6.2 % of the total pharmaceutical market in value and 8.6 % in volume terms, respectively. Domestic manufacturers lead the sales structure in volume (up to 80 %), while imported PM dominate in value (up to 57 %). The top 3 medicinal plants most frequently included in PM (in 2025) are Valeriana officinalis L., Mentha piperita L., and Glycyrrhiza spp. The herbal medicinal products (HMP) with individual compounds (IC) isolated from plant materials are widely presented on the market. Of these, more than 14 % are PM with alkaloids (morphine from Papaver somniferum L., pilocarpine from Pilocarpus pennatifolius Lem., atropine from Atropa belladonna L., platyphylline from Porella biedermannii Frank Müll., vinpocetine from Vinca minor L., and paclitaxel from Taxus spp.). By 2025, the average annual growth rate exceeded 8 % in monetary terms and 2 % in packages for alkaloid-based drugs. Considering classification by pharmacotherapeutic groups, bioflavonoids (HMP) based on diosmin, hesperidin, rutin, and their combinations) lead the market in monetary terms for 2025. Sleeping and sedatives PM are leaders in unit sales. Expectorants and respiratory medications hold second place in both monetary and packages terms. The promising niche of brown algae-based medicines (kelp) is also showing dynamic growth, with sales reaching 8.9 bln rubles. Among tonic PM, phytoadaptogens hold a significant position, with sales totaling 3.4 bln rubles in value and 38.7 mln packs in volume for the 2020–2025 period. The Compound Annual Growth Rate (CAGR) for the PM market is +6 %. The category of homeopathic medicines, despite its minimal market share (1.6 %), is the most dynamic (CAGR +9 %). The category of combination drugs with PM ranks second in terms of sales (24.8 %) and 32.6 % of packages). The CAGR for this category is +3 % and the drivers with a CAGR of +12 % are PM with medicinal plant materials (MPM). The category of herbal medicines is growing by 8 % and is the clear leader in terms of packages sales (35.3 %). The herbal medicines category, while leading in terms of sales value (54.3 %), is showing moderate growth (CAGR +5 %). According to the BCG matrix estimate for 2020–2025, the only segment that occupies the "Star" position in the PM market structure is the HMP with IC (the segment accumulates 31.0 % of the total sales volume (RUB 249.2 bln) with a CAGR of 6 %). The "Cash Cows" category encompasses the largest number of segments, but the dominant positions are held by galenic HMP (tinctures, extracts, elixirs, juices, and syrups) with a CAGR of 5 % and HMP (CAGR of 8 %). Solid dosage forms predominate in the PM market, accounting for approximately 63 % by value and 44.1 % by packages. The share of tinctures and drops accounts for 13.1 % and 12.2 % in monetary terms and in packages, respectively. Conclusion. A key direction for PM Industry development is to increase the share of locally produced drugs with high added value. The strategic priority for the development of the PMs market is to support the segments of HMPs with IC, galenic HMPs and plant-based medicines (PbM), as well as scaling the segments of combinations of combined medicine (CM) with MPM as the fastest growing.